Biomarkers of DNA Damage (James A. Swenberg, D.V.M., Ph.D., Faculty Director) An exciting new area in molecular epidemiology research involves applications of biomarkers of exposure to the cancer researcher's armamentarium. These include measurement of endogenous and exogenous DNA adducts, abasic sites in DNA, protein adducts and other measures of oxidative stress. Recent methodological improvements have raised the sensitivity of many protein and DNA adduct assays, The principal objective of the new Biomarkers of DNA Damage Core is to provide facilities and expertise to generate highly specific and ultrasensitive measures of DNA damage for Cancer Center members. The Core will assist Center investigators with experimental design, tissue collection, sample preparation and analysis of various endpoints, as well as assisting in the development of preliminary data and new assays or applications of existing assays. The facility's Director, Dr. James Swenberg, is a leading investigator of biomarker research on endogenous DNA adducts. The Core will collaborate with the UNC Superfund Basic Research Program Chemistry Core, which specializes in synthesis and characterization of the chemical standards and stable isotope internal standards that are necessary for DNA and protein adduct research. The proposed Center Core Support Grant (CCSG) contribution of $55,285 will account for 12% of the facility's total budget, and primarily will support the Director (5%), a mass spectrometry expert (15%, and the Core's Research Analyst (50%). Unavailable commercially, the state-of- the-art services provided by the Biomarkers Core will encourage investigators to test hypotheses that would be very difficult to explore in individual laboratories due to the prohibitive cost of acquiring the necessary equipment and expertise.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Lee, Clara Nan-Hi; Pignone, Michael Patrick; Deal, Allison M et al. (2018) Accuracy of Predictions of Patients With Breast Cancer of Future Well-being After Immediate Breast Reconstruction. JAMA Surg 153:e176112
Ricketts, Christopher J; De Cubas, Aguirre A; Fan, Huihui et al. (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23:313-326.e5
Golden, Shelley D; Kong, Amanda Y; Lee, Joseph G L et al. (2018) Disparities in cigarette tax exposure by race, ethnicity, poverty status and sexual orientation, 2006-2014, USA. Prev Med 108:137-144
Song, Wantong; Shen, Limei; Wang, Ying et al. (2018) Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun 9:2237
Kaur, Gurpreet; Guruprasad, Kunchur; Temple, Brenda R S et al. (2018) Structural complexity and functional diversity of plant NADPH oxidases. Amino Acids 50:79-94
McNeill, Robert S; Stroobant, Emily E; Smithberger, Erin et al. (2018) PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. PLoS One 13:e0200014
Graham-Gurysh, Elizabeth; Moore, Kathryn M; Satterlee, Andrew B et al. (2018) Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Mol Pharm 15:1309-1318
Trout, Susan; Goldstein, Adam O; Marks, Lawrence et al. (2018) Treating Tobacco Use in Patients with Incurable Malignancies: Should We Even Start the Conversation? J Palliat Med 21:746-750
Swords, Ronan T; Coutre, Steven; Maris, Michael B et al. (2018) Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood 131:1415-1424
Wang, Yuhua; Zhang, Lu; Xu, Zhenghong et al. (2018) mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Mol Ther 26:420-434

Showing the most recent 10 out of 1525 publications